surmount-1 tirzepatide weight loss percent nejm 2022 For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The Zepbound Clinical Trial Results: SURMOUNT-1

At the same time, our preclinical safety evaluation studies showed that BPC157 was well tolerated and did not demonstrate any serious toxic effects in mice, rats, rabbits, or dogs (Xu et al., 2020)

GLP-1 medications like Wegovy and Zepbound have rapidly reshaped metabolic care, expanding from Type 2 diabetes treatment to widely used weight management tools when combined with diet and exercise

: : 72 : 6 (g) : 1.5 : 5 : -1 : 27% : 28% B12: 21% B2 (): 16% D: 6% : 5%

West evaluates each patients health history, weight concerns, goals, and long-term plan before recommending treatment

Phase 3 trials for obesity completed in August 2025

However, information related to pregnancy appears in Section 8.1 & 8.3 of the Prescribing Information for both Ozempic and Wegovy." A study is currently underway to evacuate the safety of Wegovy exposure during pregnancy, and is expected to be completed in August 2027